High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials
Abstract With the exception of high-dose methotrexate (HD-MTX), there is currently no defined standard treatment for newly diagnosed primary central nervous system lymphoma (PCNSL). This review focused on first-line induction and consolidation treatment of PCNSL and aimed to determine the optimal co...
Guardado en:
Autores principales: | Junyao Yu, Huaping Du, Xueshi Ye, Lifei Zhang, Haowen Xiao |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3170ff54733d4395aa0b2557dcab7c0b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Update on Novel Therapeutics for Primary CNS Lymphoma
por: Lauren R. Schaff, et al.
Publicado: (2021) -
Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis
por: Lena Öhman, et al.
Publicado: (2021) -
Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival.
por: Emmanuel Canet, et al.
Publicado: (2013) -
Clinical outcomes following intravitreal methotrexate for primary vitreoretinal lymphoma
por: Casey L. Anthony, et al.
Publicado: (2021) -
Primary CNS lymphoma in immunocompetent chinese patients and the association with chronic Hepatitis B
por: B. Noor, et al.
Publicado: (2016)